New drug targets Hard-to-Treat cancers with KRAS G12V mutation
Disease control
Ongoing
This early-phase study tests a new drug called QTX3544, alone or with another drug, in people with advanced solid tumors that have a specific KRAS G12V gene change. The main goals are to check safety and find the right dose. About 237 adults with tumors that have not responded to…
Phase: PHASE1 • Sponsor: Quanta Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:41 UTC